Long-term pegylated interferon-α-2a treatment for chronic hepatitis C in an elderly renal transplant recipient: case report and literature review.

Combination treatment of pegylated interferon (PEG-IFN) plus ribavirin for renal transplant recipients (RTRs) with hepatitis C virus (HCV) infection remains controversial, as it has been associated with a high risk of rejection, resulting in graft loss and a reduction in patient survival.We present a special case of an elderly RTR who experienced treatment of HCV infection 8 years after renal transplant. There was no rejection episode during or after PEG-IFN treatment. The patient first received a 24-week therapy and a further 60-week course due to relapse. Cessation of both courses corresponded to an achieved end-of-treatment response. However, HCV infection reappeared shortly after cessation of the 60-week treatment period.This case highlights the safety of PEG-IFN therapy for elderly RTR and the potential importance of combination pretreatment for patients undergoing renal transplantation.
AuthorsMing-Hua Zheng, Yong-Ping Chen
JournalMedicine (Medicine (Baltimore)) Vol. 94 Issue 1 Pg. e390 (Jan 2015) ISSN: 1536-5964 [Electronic] United States
PMID25569669 (Publication Type: Case Reports, Journal Article, Review)
Chemical References
  • Antiviral Agents
  • Interferon-alpha
  • Recombinant Proteins
  • peginterferon alfa-2a
  • Polyethylene Glycols
  • Antiviral Agents (therapeutic use)
  • Hepatitis C, Chronic (drug therapy)
  • Humans
  • Interferon-alpha (therapeutic use)
  • Kidney Transplantation
  • Male
  • Middle Aged
  • Polyethylene Glycols (therapeutic use)
  • Postoperative Complications (drug therapy)
  • Recombinant Proteins (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: